Mineralys Therapeutics (MLYS) CMO receives new stock options and RSUs

Rhea-AI Filing Summary

Mineralys Therapeutics reported that Chief Medical Officer David Malcom acquired new equity awards on February 19, 2026. He received 51,300 stock options with an exercise price of $0.00 per share and now holds 51,300 options in total. He also received 38,400 shares of common stock for no cash consideration, increasing his direct common share holdings to 82,489 shares. The 38,400-share grant is in the form of restricted stock units that vest in four equal annual installments on each one-year anniversary of the grant date. The stock options vest separately in 48 equal monthly installments over four years following the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	51,300	$0.00	--
Grant/Award	Common Stock	38,400	$0.00	--

Holdings After Transaction: Stock Option — 51,300 shares (Direct); Common Stock — 82,489 shares (Direct)

Footnotes (1)

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		A		38,400(1)	A	$0	82,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$28.06	02/19/2026		A		51,300		(2)	02/19/2036	Common Stock	51,300	$0	51,300	D

Explanation of Responses:

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.

2. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant

Remarks:

	/s/ Adam Levy, Attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Mineralys Therapeutics (MLYS) report for its CMO?

Mineralys Therapeutics reported that Chief Medical Officer David Malcom received equity awards. He was granted 51,300 stock options and 38,400 restricted stock units, both for no cash consideration, as part of his compensation package on February 19, 2026.

How many stock options did the Mineralys Therapeutics (MLYS) CMO receive?

Chief Medical Officer David Malcom received 51,300 stock options. These options vest over four years in 48 equal monthly installments, beginning after the February 19, 2026 grant date, aligning his incentives with longer-term company performance.

What is the vesting schedule for the Mineralys Therapeutics (MLYS) CMO’s restricted stock units?

The 38,400 restricted stock units granted to the CMO vest over four years. One quarter of the total RSUs vests on each one-year anniversary of the February 19, 2026 grant date, with each vested unit converting into one share of common stock.

How many Mineralys Therapeutics (MLYS) common shares does the CMO own after this Form 4?

After the reported grants, Chief Medical Officer David Malcom directly holds 82,489 shares of common stock. This total includes the newly granted 38,400 restricted stock units, which will settle into common shares as they vest over four years.

Were the Mineralys Therapeutics (MLYS) equity awards to the CMO purchased in the open market?

No, the equity awards were not open‑market purchases. The Form 4 shows the stock options and restricted stock units were granted for no additional cash consideration as part of the CMO’s compensation on February 19, 2026.

What does the Form 4 reveal about Mineralys Therapeutics (MLYS) executive compensation structure?

The Form 4 shows Mineralys Therapeutics uses equity-based compensation for executives. The CMO received both time‑vested stock options and restricted stock units, vesting monthly and annually over four years, linking compensation to continued service and long‑term company performance.